Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33387086)

  • 1. Comprehensive analysis of genomic alterations of Chinese hilar cholangiocarcinoma patients.
    Feng F; Wu X; Shi X; Gao Q; Wu Y; Yu Y; Cheng Q; Li B; Yi B; Liu C; Hao Q; Zhang L; Gao C; Jiang X
    Int J Clin Oncol; 2021 Apr; 26(4):717-727. PubMed ID: 33387086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific genomic alterations and prognostic analysis of perihilar cholangiocarcinoma and distal cholangiocarcinoma.
    Zheng Y; Qin Y; Gong W; Li H; Li B; Wang Y; Chao B; Zhao S; Liu L; Yao S; Shi J; Shi X; Wang K; Xu S
    J Gastrointest Oncol; 2021 Dec; 12(6):2631-2642. PubMed ID: 35070393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of genomic alterations in Chinese cholangiocarcinoma patients.
    Jiang G; Zhang W; Wang T; Ding S; Shi X; Zhang S; Shi W; Liu A; Zheng S
    Jpn J Clin Oncol; 2020 Sep; 50(10):1117-1125. PubMed ID: 32533190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation spectrum associated with metastasis of advanced cholangiocarcinoma.
    Song H; Huang Y; Jiang X
    J Int Med Res; 2022 Jun; 50(6):3000605221102080. PubMed ID: 35726602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational spectrum and precision oncology for biliary tract carcinoma.
    Lin J; Cao Y; Yang X; Li G; Shi Y; Wang D; Long J; Song Y; Mao J; Xie F; Bai Y; Zhang L; Yang X; Wan X; Wang A; Guan M; Zhao L; Hu K; Pan J; Huo L; Lu X; Mao Y; Sang X; Zhang H; Wang K; Wang X; Zhao H
    Theranostics; 2021; 11(10):4585-4598. PubMed ID: 33754015
    [No Abstract]   [Full Text] [Related]  

  • 6. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
    Churi CR; Shroff R; Wang Y; Rashid A; Kang HC; Weatherly J; Zuo M; Zinner R; Hong D; Meric-Bernstam F; Janku F; Crane CH; Mishra L; Vauthey JN; Wolff RA; Mills G; Javle M
    PLoS One; 2014; 9(12):e115383. PubMed ID: 25536104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
    Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
    Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular profiling and prognostic analysis in Chinese cholangiocarcinoma: an observational, retrospective single-center study.
    Zhang C; You X; Zhang Q; Wang D
    Invest New Drugs; 2024 Feb; 42(1):24-34. PubMed ID: 37975978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic and transcriptional alterations of cholangiocarcinoma.
    Ito T; Sakurai-Yageta M; Goto A; Pairojkul C; Yongvanit P; Murakami Y
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):380-7. PubMed ID: 24532422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment and characterization of a novel hilar cholangiocarcinoma cell line, CBC3T-1.
    Bai M; Jiang N; Fu W; Huang C; Tian L; Mi N; Gao L; Ma H; Lu Y; Cao J; Zhang C; Yue P; Zhang Y; Lin Y; Meng W; Li X
    Hum Cell; 2024 Jan; 37(1):364-375. PubMed ID: 37966669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive genomic profile of cholangiocarcinomas in China.
    Tian W; Hu W; Shi X; Liu P; Ma X; Zhao W; Qu L; Zhang S; Shi W; Liu A; Cao J
    Oncol Lett; 2020 Apr; 19(4):3101-3110. PubMed ID: 32256810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of genomic alterations in Chinese colorectal cancer patients.
    Huang W; Li H; Shi X; Lin M; Liao C; Zhang S; Shi W; Zhang L; Zhang X; Gan J
    Jpn J Clin Oncol; 2021 Jan; 51(1):120-129. PubMed ID: 33106877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets.
    Lee H; Wang K; Johnson A; Jones DM; Ali SM; Elvin JA; Yelensky R; Lipson D; Miller VA; Stephens PJ; Javle M; Ross JS
    J Clin Pathol; 2016 May; 69(5):403-8. PubMed ID: 26500333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical considerations in screening for genetic alterations in cholangiocarcinoma.
    Bekaii-Saab TS; Bridgewater J; Normanno N
    Ann Oncol; 2021 Sep; 32(9):1111-1126. PubMed ID: 33932504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis of cholangiocarcinoma: From genetics to signalling pathways.
    Kongpetch S; Jusakul A; Ong CK; Lim WK; Rozen SG; Tan P; Teh BT
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):233-44. PubMed ID: 25966424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
    Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
    J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinically significant genomic alterations in the Chinese and Western patients with intrahepatic cholangiocarcinoma.
    Xu S; Guo Y; Zeng Y; Song Z; Zhu X; Fan N; Zhang Z; Ren G; Zang Y; Rao W
    BMC Cancer; 2021 Feb; 21(1):152. PubMed ID: 33579226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker.
    Plum PS; Hess T; Bertrand D; Morgenstern I; Velazquez Camacho O; Jonas C; Alidousty C; Wagner B; Roessler S; Albrecht T; Becker J; Richartz V; Holz B; Hoppe S; Poh HM; Chia BKH; Chan CX; Pathiraja T; Teo AS; Marquardt JU; Khng A; Heise M; Fei Y; Thieme R; Klein S; Hong JH; Dima SO; Popescu I; Hoppe-Lotichius M; Buettner R; Lautem A; Otto G; Quaas A; Nagarajan N; Rozen S; Teh BT; Goeppert B; Drebber U; Lang H; Tan P; Gockel I; Schumacher J; Hillmer AM
    Clin Transl Med; 2024 Jun; 14(6):e1723. PubMed ID: 38877653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay.
    Arnold A; Bahra M; Lenze D; Bradtmöller M; Guse K; Gehlhaar C; Bläker H; Heppner FL; Koch A
    Exp Mol Pathol; 2015 Oct; 99(2):344-53. PubMed ID: 26260902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.
    Ross JS; Wang K; Gay L; Al-Rohil R; Rand JV; Jones DM; Lee HJ; Sheehan CE; Otto GA; Palmer G; Yelensky R; Lipson D; Morosini D; Hawryluk M; Catenacci DV; Miller VA; Churi C; Ali S; Stephens PJ
    Oncologist; 2014 Mar; 19(3):235-42. PubMed ID: 24563076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.